Browse Negotiations Image Banner

Banner Text Velit velaliquam, ultricies eros dolore magna in in doming ullamco sint. Sint doming dignissim in quis pariatur consequat urna eu providerent. Sint dolore ea urna velit doming ea pulvinar.

General Callout

Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.

Accordion

Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.

Heading 1

Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.

Heading 2

Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.

Related content

Dolor commodo suscipit adipiscing suscipit, elit dolore velit. Amet tempuribud velit pariatur ullamco exercitation esse dolore sint velaliquam adipiscing eu pulvinar doming sunt, dignissim velit voluptate ex suscipit sunt ex, duis dignissim nunc tempuribud laboris commodo velit ut. Velit in harmud quis voluptate esse nulla.

Shop Now!

Laboris quis consectetur sed eros velit tempuribud suscipit magna ea consequat laboris. Elit adipiscing quis sunt duis magna nulla velit amet elit ex providerent consectetur tempuribud amet ex commodo urna, magna adipiscing elit sed duis nisi pulvinar, doming pariatur velaliquam quis providerent fugiat ea aliquip sit ut nisi sunt pulvinar eu velit.

grey rec centre

Call to action

Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate

Primary Button Secondary Button

Search by drug, manufacturer, or indication

Displaying 881 - 890 of 1165

Lancora (ivabradine)

Status:

Concluded with an LOI

Manufacturer:

Servier Canada Inc.

Indication:

Heart failure, NYHA class II or III

Last updated August 22, 2018

Actikerall (fluorouracil/salicylic acid)

Status:

Concluded with an LOI

Manufacturer:

Cipher

Indication:

Hyperkeratotic actinic keratosis

Last updated August 22, 2018

Rituxan SC (rituximab)

Status:

Concluded with an LOI

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Chronic lymphocytic leukemia

Last updated August 13, 2018

Revestive (teduglutide)

Status:

Concluded with an LOI

Manufacturer:

Shire Pharma Canada ULC

Indication:

Short Bowel Syndrome (SBS)

Last updated August 7, 2018

Praluent (alirocumab)

Status:

Concluded with an LOI

Manufacturer:

Sanofi-Aventis Canada Inc.

Indication:

Primary hypercholesterolemia (non-familial and heterozygous familial)

Last updated August 2, 2018

Tagrisso (osimertinib)

Status:

Concluded with an LOI

Manufacturer:

AstraZeneca Canada Inc.

Indication:

Non-Squamous Non-Small Cell Lung Cancer

Last updated July 30, 2018

Renflexis (infliximab)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

Rheumatic Conditions

Last updated July 27, 2018

Tresiba (insulin degludec)

Status:

Concluded with an LOI

Manufacturer:

Novo Nordisk Canada Inc.

Indication:

Diabetes Mellitus, Type 1 & 2

Last updated July 26, 2018

Pomalyst (pomalidomide)

Status:

Concluded with an LOI

Manufacturer:

Celgene Inc.

Indication:

Multiple Myeloma

Last updated July 25, 2018

Procysbi (cysteamine bitartrate)

Status:

Concluded with an LOI

Manufacturer:

Horizon Therapeutics Ireland DAC

Indication:

Nephropathic cystinosis

Last updated July 20, 2018